FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162407486> ?p ?o ?g. }

• W2162407486 endingPage "1211" @default.
• W2162407486 startingPage "1203" @default.
• W2162407486 abstract "BackgroundIn women with node-positive breast cancer, the Breast International Group (BIG) 02-98 tested the incorporation of docetaxel (Taxotere) into doxorubicin (Adriamycin)-based chemotherapy, and compared sequential and concurrent docetaxel. At 5 years, there was a trend for improved disease-free survival (DFS) with docetaxel. We present results at 8-year median follow-up and exploratory analyses within biologically defined subtypes.MethodsPatients were randomly assigned to one of four treatments: (i) sequential control: doxorubicin (A) (75 mg/m2) × 4 →classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF); (ii) concurrent control: doxorubicin, cyclophosphamide (AC)(60/600 mg/m2) × 4 →CMF; (iii) sequential docetaxel: A (75 mg/m2) × 3 → docetaxel (T) (100 mg/m2) × 3 → CMF and (iv) concurrent docetaxel: AT(50/75 mg/m2) × 4 →CMF. The primary comparison evaluated docetaxel efficacy regardless of the schedule. Exploratory analyses were undertaken within biologically defined subtypes.ResultsTwo thousand eight hundred and eighty-seven patients were enrolled. After 93.4 months of median follow-up, there were 916 DFS events. For the primary comparison, there was no significant improvement in DFS from docetaxel [hazard ratio (HR) = 0.91, 95% confidence interval (CI) = 0.80–1.05, P = 0.187]. In secondary comparisons, sequential docetaxel significantly improved DFS compared with sequential control (HR = 0.81, 95% CI = 0.67–0.99, P = 0.036), and significantly improved DFS (HR = 0.84, 95% CI = 0.72–0.99, P = 0.035) and overall survival (OS) (HR = 0.79, 95% CI = 0.65–0.98, P = 0.028) compared with concurrent doxorubicin–docetaxel. Luminal-A disease had the best prognosis. HRs favored addition of sequential docetaxel in all subtypes, except luminal-A; but this observation was not statistically supported because of limited numbers.ConclusionWith further follow-up, the sequential docetaxel schedule resulted in significantly better OS than concurrent doxorubicin–docetaxel, and continued to show better DFS than sequential doxorubicin-based control." @default.
• W2162407486 created "2016-06-24" @default.
• W2162407486 creator A5006908391 @default.
• W2162407486 creator A5012187098 @default.
• W2162407486 creator A5012452403 @default.
• W2162407486 creator A5021171228 @default.
• W2162407486 creator A5025224681 @default.
• W2162407486 creator A5027201197 @default.
• W2162407486 creator A5034917860 @default.
• W2162407486 creator A5035921302 @default.
• W2162407486 creator A5040290360 @default.
• W2162407486 creator A5043292277 @default.
• W2162407486 creator A5044226022 @default.
• W2162407486 creator A5058112962 @default.
• W2162407486 creator A5058767202 @default.
• W2162407486 creator A5061698687 @default.
• W2162407486 creator A5067552665 @default.
• W2162407486 creator A5068091207 @default.
• W2162407486 creator A5076132601 @default.
• W2162407486 creator A5081663693 @default.
• W2162407486 creator A5085474533 @default.
• W2162407486 creator A5088697304 @default.
• W2162407486 creator A5089297236 @default.
• W2162407486 date "2013-05-01" @default.
• W2162407486 modified "2023-10-17" @default.
• W2162407486 title "Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial" @default.
• W2162407486 cites W1701849548 @default.
• W2162407486 cites W2055468688 @default.
• W2162407486 cites W2058680863 @default.
• W2162407486 cites W2075213874 @default.
• W2162407486 cites W2084370697 @default.
• W2162407486 cites W2089265205 @default.
• W2162407486 cites W2097255042 @default.
• W2162407486 cites W2097996372 @default.
• W2162407486 cites W2098333537 @default.
• W2162407486 cites W2107928330 @default.
• W2162407486 cites W2109497907 @default.
• W2162407486 cites W2115228053 @default.
• W2162407486 cites W2117151785 @default.
• W2162407486 cites W2123528875 @default.
• W2162407486 cites W2125835228 @default.
• W2162407486 cites W2125955497 @default.
• W2162407486 cites W2127057139 @default.
• W2162407486 cites W2127232551 @default.
• W2162407486 cites W2135800076 @default.
• W2162407486 cites W2136655134 @default.
• W2162407486 cites W2141056749 @default.
• W2162407486 cites W2149876820 @default.
• W2162407486 cites W2150134401 @default.
• W2162407486 cites W2150706560 @default.
• W2162407486 cites W2164122193 @default.
• W2162407486 doi "https://doi.org/10.1093/annonc/mds627" @default.
• W2162407486 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23293111" @default.
• W2162407486 hasPublicationYear "2013" @default.
• W2162407486 type Work @default.
• W2162407486 sameAs 2162407486 @default.
• W2162407486 citedByCount "19" @default.
• W2162407486 countsByYear W21624074862013 @default.
• W2162407486 countsByYear W21624074862014 @default.
• W2162407486 countsByYear W21624074862015 @default.
• W2162407486 countsByYear W21624074862016 @default.
• W2162407486 countsByYear W21624074862017 @default.
• W2162407486 countsByYear W21624074862018 @default.
• W2162407486 countsByYear W21624074862019 @default.
• W2162407486 countsByYear W21624074862021 @default.
• W2162407486 countsByYear W21624074862022 @default.
• W2162407486 countsByYear W21624074862023 @default.
• W2162407486 crossrefType "journal-article" @default.
• W2162407486 hasAuthorship W2162407486A5006908391 @default.
• W2162407486 hasAuthorship W2162407486A5012187098 @default.
• W2162407486 hasAuthorship W2162407486A5012452403 @default.
• W2162407486 hasAuthorship W2162407486A5021171228 @default.
• W2162407486 hasAuthorship W2162407486A5025224681 @default.
• W2162407486 hasAuthorship W2162407486A5027201197 @default.
• W2162407486 hasAuthorship W2162407486A5034917860 @default.
• W2162407486 hasAuthorship W2162407486A5035921302 @default.
• W2162407486 hasAuthorship W2162407486A5040290360 @default.
• W2162407486 hasAuthorship W2162407486A5043292277 @default.
• W2162407486 hasAuthorship W2162407486A5044226022 @default.
• W2162407486 hasAuthorship W2162407486A5058112962 @default.
• W2162407486 hasAuthorship W2162407486A5058767202 @default.
• W2162407486 hasAuthorship W2162407486A5061698687 @default.
• W2162407486 hasAuthorship W2162407486A5067552665 @default.
• W2162407486 hasAuthorship W2162407486A5068091207 @default.
• W2162407486 hasAuthorship W2162407486A5076132601 @default.
• W2162407486 hasAuthorship W2162407486A5081663693 @default.
• W2162407486 hasAuthorship W2162407486A5085474533 @default.
• W2162407486 hasAuthorship W2162407486A5088697304 @default.
• W2162407486 hasAuthorship W2162407486A5089297236 @default.
• W2162407486 hasBestOaLocation W21624074861 @default.
• W2162407486 hasConcept C121608353 @default.
• W2162407486 hasConcept C126322002 @default.
• W2162407486 hasConcept C143998085 @default.
• W2162407486 hasConcept C207103383 @default.
• W2162407486 hasConcept C2776694085 @default.
• W2162407486 hasConcept C2776755627 @default.
• W2162407486 hasConcept C2777292972 @default.
• W2162407486 hasConcept C2781190966 @default.

• next